Endologix today announced that it has completed its acquisition of PQ Bypass for an undisclosed amount.
PQ Bypass makes the Detour platform that is designed for percutaneous femoral-popliteal bypass, which has been designated as a breakthrough device by the FDA.
The Detour system has the company’s Torus stent graft and the PQ crossing device. It is currently being studied in a U.S. and European clinical trial.
